Mazindol

Mazindol

Mazindol (MZD) is a norepinephrine reuptake inhibitor previously approved by the FDA for the treatment of obesity, with 10 studies supporting the safety and efficacy of MZD 1 mg to 3 mg. Since the CNS noradrenergic and dopaminergic systems appear to be dysfunctional in ADHD and an open-label trial of mazindol demonstrated efficacy in improving the symptoms of pediatrics with ADHD, NLS-1 seeks to confirm the efficacy, tolerability and safety of mazindol C.R. in the treatment of DSM-V Attention Deficit Disorder in adults and pediatrics.